Successful Long-Term Treatment of TMA with Eculizumab in a Transplanted Patient with Atypical Hemolytic Uremic Syndrome Due to MCP Mutation

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

(2013) C.M. Legendre et al.   NEW ENGLAND JOURNAL OF MEDICINE

Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation

(2012) J. Zuber et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies

(2012) Julien Zuber et al.   Nature Reviews Nephrology

Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft

(2012) Nada Alachkar et al.   TRANSPLANT INTERNATIONAL

Eculizumab: Safety and Efficacy After 17 Months of Treatment in a Renal Transplant Patient With Recurrent Atypical Hemolytic-Uremic Syndrome: Case Report

(2010) V. Châtelet et al.   TRANSPLANTATION PROCEEDINGS

Safety and Long-Term Efficacy of Eculizumab in a Renal Transplant Patient with Recurrent Atypical Hemolytic-Uremic Syndrome

(2009)   AMERICAN JOURNAL OF TRANSPLANTATION

Atypical Hemolytic–Uremic Syndrome

(2009) Marina Noris et al.   NEW ENGLAND JOURNAL OF MEDICINE